Predicting Concussion Outcomes With Salivary miRNA

Sponsor
Milton S. Hershey Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT02901821
Collaborator
(none)
700
1
116
6

Study Details

Study Description

Brief Summary

The purpose of this study is to identify changes in salivary ribosomal nucleic acid (RNA) expression that are predictive of symptom duration and character following mild traumatic brain injury (mTBI) in children.

Condition or Disease Intervention/Treatment Phase
  • Genetic: salivary RNA collection

Detailed Description

The purpose of this study is to characterize longitudinal salivary RNA expression in 600 children with mTBI and identify RNA patterns that predict length and characterof concussive symptoms, as well as the response to therapy.

Hypothesis: Specific RNAs will be differentially regulated in children with prolonged mTBI symptoms across the acute and sub-acute time periods. The investigators predict that a set of RNAs with differential expression in children with mTBI will be statistically associated with functional measures of mTBI symptoms as well as the duration of concussive symptoms.

Rationale: Preliminary studies show that miRNA is altered in adults with varying degrees of TBI and that salivary RNA is altered by disorders of the CNS. These studies indicate that serum-based miRNA may be used as an accurate biomarker for differentiating adults with and without TBI. Whether similar patterns can seen in the saliva of children following mTBI remains to be seen. Furthermore, the influence of confounding variables such as gender, mechanism of injury, and previous mTBIs on RNA profiles has not been explored. The investigators propose to investigate these questions by examining salivary RNA from 600 children (ages five to twenty-one years) with a clinical diagnosis of mTBI (as well as 100 age-and gender-matched controls, recruited from the Penn State Pediatric Concussion Clinic, Emergency Department, and the affiliated primary care clinics). The investigators plan to prospectively follow 600 children with mTBI for 1-month post-concussion, tracking subjective symptoms with the Child Sports Concussion Assessment Tool (SCAT-5), and objective symptoms of balance and cognition. Saliva will be collected via swab at three time-points (at initial clinical presentation, 1-2 weeks, and 4-weeks after the date of initial mTBI). Expression of salivary RNA taken at initial presentation will be compared against symptom duration (where prolonged post-concussive symptoms are defined as those lasting >4 weeks) and character (as measured numerically by Post-concussion symptom inventory self-report and ClearEdge scoring). The investigators plan to identify a set of salivary RNAs that can easily be used to predict clinical course for pediatric patients following a diagnosis of mTBI.

Study Design

Study Type:
Observational
Anticipated Enrollment :
700 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Predicting Concussion Outcomes With Salivary miRNA
Actual Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Control

No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).

Genetic: salivary RNA collection
collection of saliva for microRNA (small noncoding RNA) processing

Concussion

Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.

Genetic: salivary RNA collection
collection of saliva for microRNA (small noncoding RNA) processing

Outcome Measures

Primary Outcome Measures

  1. Presence or absence of concussion symptoms [4-weeks post injury]

    subjective (score >7 on PCSI) or objective (score outside 85 percentile on accelerometer balance testing or cognitive testing)

Secondary Outcome Measures

  1. Salivary RNA profile [Within 7d of initial injury, 1-2 weeks post-injury, and 4-weeks post-injury]

    measured with RNAseq

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 5-21 years with mild traumatic brain injury that occurred within 7 days of enrollment
Exclusion Criteria:
  • Sever traumatic brain injury

  • Skull fracture

  • Concurrent upper respiratory infection

  • Patients whose primary language is not English

  • Periodontal infection

  • Wards of the state

  • Ongoing seizure disorder,

  • Drug or alcohol dependency

Contacts and Locations

Locations

Site City State Country Postal Code
1 Penn State Milton S. Hershey Medical Center Hershey Pennsylvania United States 17033

Sponsors and Collaborators

  • Milton S. Hershey Medical Center

Investigators

  • Principal Investigator: Steven Hicks, MD, PhD, Milton S. Hershey Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Steven Hicks, Assistant Professor of Pediatrics, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier:
NCT02901821
Other Study ID Numbers:
  • STUDY00003729
First Posted:
Sep 15, 2016
Last Update Posted:
Sep 27, 2021
Last Verified:
Sep 1, 2021
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2021